#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Genome-wide DNA methylation patterns and methylation abnormalities in pituitary tumors have been reported previously .
3-1	15-26	Genome-wide	abstract[5]	new[5]	_	_
3-2	27-30	DNA	abstract|abstract[5]	new|new[5]	coref	5-22
3-3	31-42	methylation	abstract|abstract[5]	new|new[5]	coref	3-6
3-4	43-51	patterns	abstract[5]	new[5]	_	_
3-5	52-55	and	_	_	_	_
3-6	56-67	methylation	abstract|abstract[7]	giv|new[7]	coref|coref	4-9[12_0]|4-9[12_0]
3-7	68-81	abnormalities	abstract[7]	new[7]	_	_
3-8	82-84	in	abstract[7]	new[7]	_	_
3-9	85-94	pituitary	abstract[7]|place|object[9]	new[7]|new|new[9]	coref|coref|coref|coref	5-33[0_9]|6-12|5-33[0_9]|6-12
3-10	95-101	tumors	abstract[7]|object[9]	new[7]|new[9]	_	_
3-11	102-106	have	_	_	_	_
3-12	107-111	been	_	_	_	_
3-13	112-120	reported	_	_	_	_
3-14	121-131	previously	_	_	_	_
3-15	132-133	.	_	_	_	_

#Text=To date , however , the impact of aberrant CpG methylation on gene expression in NFPAs has not been investigated by a multi-omics approach .
4-1	134-136	To	_	_	_	_
4-2	137-141	date	time	new	_	_
4-3	142-143	,	_	_	_	_
4-4	144-151	however	_	_	_	_
4-5	152-153	,	_	_	_	_
4-6	154-157	the	abstract[11]	new[11]	_	_
4-7	158-164	impact	abstract[11]	new[11]	_	_
4-8	165-167	of	abstract[11]	new[11]	_	_
4-9	168-176	aberrant	abstract[11]|abstract[12]	new[11]|giv[12]	coref	5-22[27_12]
4-10	177-180	CpG	abstract[11]|abstract[12]	new[11]|giv[12]	_	_
4-11	181-192	methylation	abstract[11]|abstract[12]	new[11]|giv[12]	_	_
4-12	193-195	on	abstract[11]|abstract[12]	new[11]|giv[12]	_	_
4-13	196-200	gene	abstract[11]|abstract[12]|abstract|abstract[14]	new[11]|giv[12]|new|new[14]	coref|coref|coref|coref	5-37[0_14]|10-9|5-37[0_14]|10-9
4-14	201-211	expression	abstract[11]|abstract[12]|abstract[14]	new[11]|giv[12]|new[14]	_	_
4-15	212-214	in	abstract[11]|abstract[12]|abstract[14]	new[11]|giv[12]|new[14]	_	_
4-16	215-220	NFPAs	abstract[11]|abstract[12]|abstract[14]|object	new[11]|giv[12]|new[14]|new	coref	7-15
4-17	221-224	has	_	_	_	_
4-18	225-228	not	_	_	_	_
4-19	229-233	been	_	_	_	_
4-20	234-246	investigated	_	_	_	_
4-21	247-249	by	_	_	_	_
4-22	250-251	a	abstract[17]	new[17]	_	_
4-23	252-263	multi-omics	abstract|abstract[17]	new|new[17]	_	_
4-24	264-272	approach	abstract[17]	new[17]	_	_
4-25	273-274	.	_	_	_	_

#Text=In this study , we combined the results of methylome and transcriptome profiling of 33 gonadotroph NFPA samples to investigate whether DNA methylation at particular CpGs that are aberrantly methylated in gonadotroph tumors correlates with the expression levels of the corresponding genes .
5-1	275-277	In	_	_	_	_
5-2	278-282	this	abstract[18]	new[18]	coref	23-2[194_18]
5-3	283-288	study	abstract[18]	new[18]	_	_
5-4	289-290	,	_	_	_	_
5-5	291-293	we	person	acc	ana	7-2
5-6	294-302	combined	_	_	_	_
5-7	303-306	the	abstract[20]	new[20]	coref	16-1[128_20]
5-8	307-314	results	abstract[20]	new[20]	_	_
5-9	315-317	of	abstract[20]	new[20]	_	_
5-10	318-327	methylome	abstract[20]|abstract	new[20]|new	_	_
5-11	328-331	and	_	_	_	_
5-12	332-345	transcriptome	substance|object[23]	new|new[23]	_	_
5-13	346-355	profiling	object[23]	new[23]	_	_
5-14	356-358	of	object[23]	new[23]	_	_
5-15	359-361	33	object[23]|quantity[25]	new[23]|new[25]	_	_
5-16	362-373	gonadotroph	object[23]|quantity[25]	new[23]|new[25]	_	_
5-17	374-378	NFPA	object[23]|substance|quantity[25]	new[23]|new|new[25]	_	_
5-18	379-386	samples	object[23]|quantity[25]	new[23]|new[25]	_	_
5-19	387-389	to	_	_	_	_
5-20	390-401	investigate	_	_	_	_
5-21	402-409	whether	_	_	_	_
5-22	410-413	DNA	abstract|abstract[27]	giv|giv[27]	coref|coref|coref|coref	6-7|6-7[37_27]|6-7|6-7[37_27]
5-23	414-425	methylation	abstract[27]	giv[27]	_	_
5-24	426-428	at	abstract[27]	giv[27]	_	_
5-25	429-439	particular	abstract[27]|abstract[28]	giv[27]|new[28]	coref	6-20[41_28]
5-26	440-444	CpGs	abstract[27]|abstract[28]	giv[27]|new[28]	_	_
5-27	445-449	that	_	_	_	_
5-28	450-453	are	_	_	_	_
5-29	454-464	aberrantly	_	_	_	_
5-30	465-475	methylated	_	_	_	_
5-31	476-478	in	_	_	_	_
5-32	479-490	gonadotroph	person[30]	new[30]	_	_
5-33	491-497	tumors	object|person[30]	giv|new[30]	coref	7-25
5-34	498-508	correlates	person[30]	new[30]	_	_
5-35	509-513	with	_	_	_	_
5-36	514-517	the	abstract[32]	new[32]	_	_
5-37	518-528	expression	abstract|abstract[32]	giv|new[32]	coref	8-27[58_0]
5-38	529-535	levels	abstract[32]	new[32]	_	_
5-39	536-538	of	abstract[32]	new[32]	_	_
5-40	539-542	the	abstract[32]|abstract[33]	new[32]|new[33]	coref	7-19[47_33]
5-41	543-556	corresponding	abstract[32]|abstract[33]	new[32]|new[33]	_	_
5-42	557-562	genes	abstract[32]|abstract[33]	new[32]|new[33]	_	_
5-43	563-564	.	_	_	_	_

#Text=Gonadotroph NFPAs exhibited an increase in DNA methylation relative to normal pituitary sections , and a large number of differentially methylated CpGs have been identified .
6-1	565-576	Gonadotroph	person[34]	new[34]	_	_
6-2	577-582	NFPAs	person[34]	new[34]	_	_
6-3	583-592	exhibited	_	_	_	_
6-4	593-595	an	abstract[35]	new[35]	_	_
6-5	596-604	increase	abstract[35]	new[35]	_	_
6-6	605-607	in	abstract[35]	new[35]	_	_
6-7	608-611	DNA	abstract[35]|abstract|abstract[37]	new[35]|giv|giv[37]	coref|coref|coref|coref	8-5[51_37]|10-6|8-5[51_37]|10-6
6-8	612-623	methylation	abstract[35]|abstract[37]	new[35]|giv[37]	_	_
6-9	624-632	relative	abstract[35]|abstract[37]	new[35]|giv[37]	_	_
6-10	633-635	to	_	_	_	_
6-11	636-642	normal	plant[39]	new[39]	coref	8-21[57_39]
6-12	643-652	pituitary	person|plant[39]	giv|new[39]	coref	8-21
6-13	653-661	sections	plant[39]	new[39]	_	_
6-14	662-663	,	_	_	_	_
6-15	664-667	and	_	_	_	_
6-16	668-669	a	abstract[40]	new[40]	_	_
6-17	670-675	large	abstract[40]	new[40]	_	_
6-18	676-682	number	abstract[40]	new[40]	_	_
6-19	683-685	of	abstract[40]	new[40]	_	_
6-20	686-700	differentially	abstract[40]|abstract[41]	new[40]|giv[41]	coref	7-9[0_41]
6-21	701-711	methylated	abstract[40]|abstract[41]	new[40]|giv[41]	_	_
6-22	712-716	CpGs	abstract[40]|abstract[41]	new[40]|giv[41]	_	_
6-23	717-721	have	_	_	_	_
6-24	722-726	been	_	_	_	_
6-25	727-737	identified	_	_	_	_
6-26	738-739	.	_	_	_	_

#Text=In our analysis , approximately 85 % of CpGs that are differentially methylated in NFPAs and associated with known human genes were hypermethylated in tumors .
7-1	740-742	In	_	_	_	_
7-2	743-746	our	person|abstract[43]	giv|new[43]	ana|coref|ana|coref	8-1|8-1[50_43]|8-1|8-1[50_43]
7-3	747-755	analysis	abstract[43]	new[43]	_	_
7-4	756-757	,	_	_	_	_
7-5	758-771	approximately	quantity[44]	new[44]	_	_
7-6	772-774	85	quantity[44]	new[44]	_	_
7-7	775-776	%	quantity[44]	new[44]	_	_
7-8	777-779	of	quantity[44]	new[44]	_	_
7-9	780-784	CpGs	quantity[44]|abstract	new[44]|giv	coref	8-12
7-10	785-789	that	_	_	_	_
7-11	790-793	are	_	_	_	_
7-12	794-808	differentially	_	_	_	_
7-13	809-819	methylated	_	_	_	_
7-14	820-822	in	_	_	_	_
7-15	823-828	NFPAs	substance	giv	coref	23-11
7-16	829-832	and	_	_	_	_
7-17	833-843	associated	_	_	_	_
7-18	844-848	with	_	_	_	_
7-19	849-854	known	abstract[47]	giv[47]	coref	8-30[59_47]
7-20	855-860	human	abstract[47]	giv[47]	_	_
7-21	861-866	genes	abstract[47]	giv[47]	_	_
7-22	867-871	were	_	_	_	_
7-23	872-887	hypermethylated	_	_	_	_
7-24	888-890	in	_	_	_	_
7-25	891-897	tumors	object	giv	coref	11-45[90_0]
7-26	898-899	.	_	_	_	_

#Text=Our correlation-based analysis revealed that methylation of a major fraction of CpGs that are differentially methylated in gonadotroph adenomas and pituitary sections did not correlate with the expression of the annotated genes .
8-1	900-903	Our	person|abstract[50]	giv|giv[50]	coref|ana|coref|ana	9-7[61_50]|10-1|9-7[61_50]|10-1
8-2	904-921	correlation-based	abstract[50]	giv[50]	_	_
8-3	922-930	analysis	abstract[50]	giv[50]	_	_
8-4	931-939	revealed	_	_	_	_
8-5	940-944	that	abstract[51]	giv[51]	coref	10-6[66_51]
8-6	945-956	methylation	abstract[51]	giv[51]	_	_
8-7	957-959	of	abstract[51]	giv[51]	_	_
8-8	960-961	a	abstract[51]|quantity[52]	giv[51]|new[52]	_	_
8-9	962-967	major	abstract[51]|quantity[52]	giv[51]|new[52]	_	_
8-10	968-976	fraction	abstract[51]|quantity[52]	giv[51]|new[52]	_	_
8-11	977-979	of	abstract[51]|quantity[52]	giv[51]|new[52]	_	_
8-12	980-984	CpGs	abstract[51]|quantity[52]|abstract	giv[51]|new[52]|giv	coref	10-16[71_0]
8-13	985-989	that	_	_	_	_
8-14	990-993	are	_	_	_	_
8-15	994-1008	differentially	_	_	_	_
8-16	1009-1019	methylated	_	_	_	_
8-17	1020-1022	in	_	_	_	_
8-18	1023-1034	gonadotroph	place[54]|object[55]	new[54]|new[55]	coref|coref|coref|coref	11-22[81_54]|11-22[82_55]|11-22[81_54]|11-22[82_55]
8-19	1035-1043	adenomas	place[54]|object[55]	new[54]|new[55]	_	_
8-20	1044-1047	and	object[55]	new[55]	_	_
8-21	1048-1057	pituitary	object[55]|person|plant[57]	new[55]|giv|giv[57]	coref|coref|coref|coref	11-22|23-13[201_57]|11-22|23-13[201_57]
8-22	1058-1066	sections	object[55]|plant[57]	new[55]|giv[57]	_	_
8-23	1067-1070	did	_	_	_	_
8-24	1071-1074	not	_	_	_	_
8-25	1075-1084	correlate	_	_	_	_
8-26	1085-1089	with	_	_	_	_
8-27	1090-1093	the	abstract[58]	giv[58]	ana	9-1[0_58]
8-28	1094-1104	expression	abstract[58]	giv[58]	_	_
8-29	1105-1107	of	abstract[58]	giv[58]	_	_
8-30	1108-1111	the	abstract[58]|abstract[59]	giv[58]|giv[59]	coref	11-9[0_59]
8-31	1112-1121	annotated	abstract[58]|abstract[59]	giv[58]|giv[59]	_	_
8-32	1122-1127	genes	abstract[58]|abstract[59]	giv[58]|giv[59]	_	_
8-33	1128-1129	.	_	_	_	_

#Text=This has also been observed in a similar analysis of other human cancers .
9-1	1130-1134	This	abstract	giv	coref	10-9[69_0]
9-2	1135-1138	has	_	_	_	_
9-3	1139-1143	also	_	_	_	_
9-4	1144-1148	been	_	_	_	_
9-5	1149-1157	observed	_	_	_	_
9-6	1158-1160	in	_	_	_	_
9-7	1161-1162	a	abstract[61]	giv[61]	coref	29-4[262_61]
9-8	1163-1170	similar	abstract[61]	giv[61]	_	_
9-9	1171-1179	analysis	abstract[61]	giv[61]	_	_
9-10	1180-1182	of	abstract[61]	giv[61]	_	_
9-11	1183-1188	other	abstract[61]|abstract[62]	giv[61]|new[62]	_	_
9-12	1189-1194	human	abstract[61]|abstract[62]	giv[61]|new[62]	_	_
9-13	1195-1202	cancers	abstract[61]|abstract[62]	giv[61]|new[62]	_	_
9-14	1203-1204	.	_	_	_	_

#Text=We observed a correlation between DNA methylation and gene expression in approximately 11 % of gene-associated CpGs with aberrant DNA methylation .
10-1	1205-1207	We	person	giv	ana	18-9
10-2	1208-1216	observed	_	_	_	_
10-3	1217-1218	a	abstract[64]	new[64]	coref	12-1[94_64]
10-4	1219-1230	correlation	abstract[64]	new[64]	_	_
10-5	1231-1238	between	abstract[64]	new[64]	_	_
10-6	1239-1242	DNA	abstract[64]|abstract|abstract[66]|abstract[67]	new[64]|giv|giv[66]|new[67]	coref|coref|coref|coref|coref|coref|coref|coref|coref	10-20|10-19[73_66]|11-12[78_67]|10-20|10-19[73_66]|11-12[78_67]|10-20|10-19[73_66]|11-12[78_67]
10-7	1243-1254	methylation	abstract[64]|abstract[66]|abstract[67]	new[64]|giv[66]|new[67]	_	_
10-8	1255-1258	and	abstract[64]|abstract[67]	new[64]|new[67]	_	_
10-9	1259-1263	gene	abstract[64]|abstract[67]|abstract|abstract[69]	new[64]|new[67]|giv|giv[69]	coref|coref|coref|coref	11-14[0_69]|14-9|11-14[0_69]|14-9
10-10	1264-1274	expression	abstract[64]|abstract[67]|abstract[69]	new[64]|new[67]|giv[69]	_	_
10-11	1275-1277	in	abstract[64]	new[64]	_	_
10-12	1278-1291	approximately	abstract[64]|quantity[70]	new[64]|new[70]	_	_
10-13	1292-1294	11	abstract[64]|quantity[70]	new[64]|new[70]	_	_
10-14	1295-1296	%	abstract[64]|quantity[70]	new[64]|new[70]	_	_
10-15	1297-1299	of	abstract[64]|quantity[70]	new[64]|new[70]	_	_
10-16	1300-1315	gene-associated	abstract[64]|quantity[70]|abstract[71]	new[64]|new[70]|giv[71]	coref	13-14[110_71]
10-17	1316-1320	CpGs	abstract[64]|quantity[70]|abstract[71]	new[64]|new[70]|giv[71]	_	_
10-18	1321-1325	with	abstract[64]|quantity[70]|abstract[71]	new[64]|new[70]|giv[71]	_	_
10-19	1326-1334	aberrant	abstract[64]|quantity[70]|abstract[71]|abstract[73]	new[64]|new[70]|giv[71]|giv[73]	coref	11-12[0_73]
10-20	1335-1338	DNA	abstract[64]|quantity[70]|abstract[71]|abstract|abstract[73]	new[64]|new[70]|giv[71]|giv|giv[73]	coref	12-5
10-21	1339-1350	methylation	abstract[64]|quantity[70]|abstract[71]|abstract[73]	new[64]|new[70]|giv[71]|giv[73]	_	_
10-22	1351-1352	.	_	_	_	_

#Text=These CpG sites are located in or near genes for which methylation and expression were previously reported to be correlated in pituitary adenomas , including STAT5A , RHOD , GALNT9 , and RASSF1 , as well as genes with previously described aberrant methylation in pituitary tumors , including CDKN1A , TP73 , and STAT3 .
11-1	1353-1358	These	place[75]	new[75]	coref	15-2[122_75]
11-2	1359-1362	CpG	abstract|place[75]	new|new[75]	_	_
11-3	1363-1368	sites	place[75]	new[75]	_	_
11-4	1369-1372	are	_	_	_	_
11-5	1373-1380	located	_	_	_	_
11-6	1381-1383	in	_	_	_	_
11-7	1384-1386	or	_	_	_	_
11-8	1387-1391	near	_	_	_	_
11-9	1392-1397	genes	abstract	giv	coref	11-38[87_0]
11-10	1398-1401	for	_	_	_	_
11-11	1402-1407	which	_	_	_	_
11-12	1408-1419	methylation	abstract|abstract[78]	giv|giv[78]	coref|coref|coref|coref	11-40[88_0]|12-4[97_78]|11-40[88_0]|12-4[97_78]
11-13	1420-1423	and	abstract[78]	giv[78]	_	_
11-14	1424-1434	expression	abstract[78]|abstract	giv[78]|giv	coref	12-9
11-15	1435-1439	were	_	_	_	_
11-16	1440-1450	previously	_	_	_	_
11-17	1451-1459	reported	_	_	_	_
11-18	1460-1462	to	_	_	_	_
11-19	1463-1465	be	_	_	_	_
11-20	1466-1476	correlated	_	_	_	_
11-21	1477-1479	in	_	_	_	_
11-22	1480-1489	pituitary	person|place[81]|object[82]	giv|giv[81]|giv[82]	coref|coref|coref	11-45|11-45|11-45
11-23	1490-1498	adenomas	place[81]|object[82]	giv[81]|giv[82]	_	_
11-24	1499-1500	,	place[81]|object[82]	giv[81]|giv[82]	_	_
11-25	1501-1510	including	place[81]|object[82]	giv[81]|giv[82]	_	_
11-26	1511-1517	STAT5A	place[81]|object[82]|abstract	giv[81]|giv[82]|new	_	_
11-27	1518-1519	,	place[81]|object[82]	giv[81]|giv[82]	_	_
11-28	1520-1524	RHOD	place[81]|object[82]|abstract	giv[81]|giv[82]|new	_	_
11-29	1525-1526	,	place[81]|object[82]	giv[81]|giv[82]	_	_
11-30	1527-1533	GALNT9	place[81]|object[82]|abstract	giv[81]|giv[82]|new	_	_
11-31	1534-1535	,	place[81]|object[82]	giv[81]|giv[82]	_	_
11-32	1536-1539	and	place[81]|object[82]	giv[81]|giv[82]	_	_
11-33	1540-1546	RASSF1	place[81]|object[82]|abstract	giv[81]|giv[82]|new	_	_
11-34	1547-1548	,	object[82]	giv[82]	_	_
11-35	1549-1551	as	object[82]	giv[82]	_	_
11-36	1552-1556	well	object[82]	giv[82]	_	_
11-37	1557-1559	as	object[82]	giv[82]	_	_
11-38	1560-1565	genes	object[82]|abstract[87]	giv[82]|giv[87]	coref	13-4[0_87]
11-39	1566-1570	with	object[82]|abstract[87]	giv[82]|giv[87]	_	_
11-40	1571-1581	previously	object[82]|abstract[87]|abstract[88]	giv[82]|giv[87]|giv[88]	coref	12-4[96_88]
11-41	1582-1591	described	object[82]|abstract[87]|abstract[88]	giv[82]|giv[87]|giv[88]	_	_
11-42	1592-1600	aberrant	object[82]|abstract[87]|abstract[88]	giv[82]|giv[87]|giv[88]	_	_
11-43	1601-1612	methylation	object[82]|abstract[87]|abstract[88]	giv[82]|giv[87]|giv[88]	_	_
11-44	1613-1615	in	object[82]|abstract[87]|abstract[88]	giv[82]|giv[87]|giv[88]	_	_
11-45	1616-1625	pituitary	object[82]|abstract[87]|abstract[88]|place|object[90]	giv[82]|giv[87]|giv[88]|giv|giv[90]	coref|coref|coref|coref	12-26|12-26[104_90]|12-26|12-26[104_90]
11-46	1626-1632	tumors	object[82]|abstract[87]|abstract[88]|object[90]	giv[82]|giv[87]|giv[88]|giv[90]	_	_
11-47	1633-1634	,	object[82]|abstract[87]|abstract[88]	giv[82]|giv[87]|giv[88]	_	_
11-48	1635-1644	including	object[82]|abstract[87]|abstract[88]	giv[82]|giv[87]|giv[88]	_	_
11-49	1645-1651	CDKN1A	object[82]|abstract[87]|abstract[88]|object	giv[82]|giv[87]|giv[88]|new	_	_
11-50	1652-1653	,	object[82]|abstract[87]|abstract[88]	giv[82]|giv[87]|giv[88]	_	_
11-51	1654-1658	TP73	object[82]|abstract[87]|abstract[88]|abstract	giv[82]|giv[87]|giv[88]|new	_	_
11-52	1659-1660	,	object[82]|abstract[87]|abstract[88]	giv[82]|giv[87]|giv[88]	_	_
11-53	1661-1664	and	object[82]|abstract[87]|abstract[88]	giv[82]|giv[87]|giv[88]	_	_
11-54	1665-1670	STAT3	object[82]|abstract[87]|abstract[88]|abstract	giv[82]|giv[87]|giv[88]|new	_	_
11-55	1671-1672	.	_	_	_	_

#Text=A correlation between aberrant DNA methylation and the expression level was also observed for HMGA2 , which plays an important role in the pathogenesis of pituitary tumors .
12-1	1673-1674	A	abstract[94]	giv[94]	coref	18-85[168_94]
12-2	1675-1686	correlation	abstract[94]	giv[94]	_	_
12-3	1687-1694	between	abstract[94]	giv[94]	_	_
12-4	1695-1703	aberrant	abstract[94]|abstract[96]|abstract[97]	giv[94]|giv[96]|giv[97]	coref|coref|coref|coref	13-11[0_96]|18-79[166_97]|13-11[0_96]|18-79[166_97]
12-5	1704-1707	DNA	abstract[94]|substance|abstract[96]|abstract[97]	giv[94]|giv|giv[96]|giv[97]	coref	22-30
12-6	1708-1719	methylation	abstract[94]|abstract[96]|abstract[97]	giv[94]|giv[96]|giv[97]	_	_
12-7	1720-1723	and	abstract[94]|abstract[97]	giv[94]|giv[97]	_	_
12-8	1724-1727	the	abstract[94]|abstract[97]|abstract[99]	giv[94]|giv[97]|new[99]	coref	13-10[109_99]
12-9	1728-1738	expression	abstract[94]|abstract[97]|abstract|abstract[99]	giv[94]|giv[97]|giv|new[99]	coref	13-5[107_0]
12-10	1739-1744	level	abstract[94]|abstract[97]|abstract[99]	giv[94]|giv[97]|new[99]	_	_
12-11	1745-1748	was	_	_	_	_
12-12	1749-1753	also	_	_	_	_
12-13	1754-1762	observed	_	_	_	_
12-14	1763-1766	for	_	_	_	_
12-15	1767-1772	HMGA2	abstract	new	_	_
12-16	1773-1774	,	_	_	_	_
12-17	1775-1780	which	_	_	_	_
12-18	1781-1786	plays	_	_	_	_
12-19	1787-1789	an	abstract[101]	new[101]	_	_
12-20	1790-1799	important	abstract[101]	new[101]	_	_
12-21	1800-1804	role	abstract[101]	new[101]	_	_
12-22	1805-1807	in	_	_	_	_
12-23	1808-1811	the	event[102]	new[102]	_	_
12-24	1812-1824	pathogenesis	event[102]	new[102]	_	_
12-25	1825-1827	of	event[102]	new[102]	_	_
12-26	1828-1837	pituitary	event[102]|place|object[104]	new[102]|giv|giv[104]	coref|coref|coref|coref	16-12[0_104]|23-14|16-12[0_104]|23-14
12-27	1838-1844	tumors	event[102]|object[104]	new[102]|giv[104]	_	_
12-28	1845-1846	.	_	_	_	_

#Text=GSEA revealed that genes whose expression was related to the methylation level of differentially methylated CpGs were enriched in pathways and processes important for tumor development .
13-1	1847-1851	GSEA	event	new	coref	27-6[244_0]
13-2	1852-1860	revealed	_	_	_	_
13-3	1861-1865	that	_	_	_	_
13-4	1866-1871	genes	abstract	giv	coref	16-28
13-5	1872-1877	whose	abstract[107]	giv[107]	coref	14-9[118_107]
13-6	1878-1888	expression	abstract[107]	giv[107]	_	_
13-7	1889-1892	was	_	_	_	_
13-8	1893-1900	related	_	_	_	_
13-9	1901-1903	to	_	_	_	_
13-10	1904-1907	the	abstract[109]	giv[109]	_	_
13-11	1908-1919	methylation	abstract|abstract[109]	giv|giv[109]	coref	14-4[116_0]
13-12	1920-1925	level	abstract[109]	giv[109]	_	_
13-13	1926-1928	of	abstract[109]	giv[109]	_	_
13-14	1929-1943	differentially	abstract[109]|abstract[110]	giv[109]|giv[110]	coref	14-2[115_110]
13-15	1944-1954	methylated	abstract[109]|abstract[110]	giv[109]|giv[110]	_	_
13-16	1955-1959	CpGs	abstract[109]|abstract[110]	giv[109]|giv[110]	_	_
13-17	1960-1964	were	_	_	_	_
13-18	1965-1973	enriched	_	_	_	_
13-19	1974-1976	in	_	_	_	_
13-20	1977-1985	pathways	abstract	new	_	_
13-21	1986-1989	and	_	_	_	_
13-22	1990-1999	processes	abstract[112]	new[112]	_	_
13-23	2000-2009	important	abstract[112]	new[112]	_	_
13-24	2010-2013	for	_	_	_	_
13-25	2014-2019	tumor	abstract|event[114]	new|new[114]	_	_
13-26	2020-2031	development	event[114]	new[114]	_	_
13-27	2032-2033	.	_	_	_	_

#Text=For most CpGs whose methylation was related to gene expression , the relationship was an inverse one :
14-1	2034-2037	For	_	_	_	_
14-2	2038-2042	most	abstract[115]	giv[115]	coref	18-14[144_115]
14-3	2043-2047	CpGs	abstract[115]	giv[115]	_	_
14-4	2048-2053	whose	abstract[116]	giv[116]	coref	16-14[131_116]
14-5	2054-2065	methylation	abstract[116]	giv[116]	_	_
14-6	2066-2069	was	_	_	_	_
14-7	2070-2077	related	_	_	_	_
14-8	2078-2080	to	_	_	_	_
14-9	2081-2085	gene	abstract|abstract[118]	giv|giv[118]	coref|coref|coref|coref	15-15|15-15[127_118]|15-15|15-15[127_118]
14-10	2086-2096	expression	abstract[118]	giv[118]	_	_
14-11	2097-2098	,	_	_	_	_
14-12	2099-2102	the	abstract[119]	new[119]	_	_
14-13	2103-2115	relationship	abstract[119]	new[119]	_	_
14-14	2116-2119	was	_	_	_	_
14-15	2120-2122	an	abstract[121]	new[121]	_	_
14-16	2123-2130	inverse	place|abstract[121]	new|new[121]	_	_
14-17	2131-2134	one	abstract[121]	new[121]	_	_
14-18	2135-2136	:	_	_	_	_

#Text=For these sites , hypermethylation and hypomethylation corresponded to a decrease and increase in gene expression , respectively .
15-1	2137-2140	For	_	_	_	_
15-2	2141-2146	these	place[122]	giv[122]	_	_
15-3	2147-2152	sites	place[122]	giv[122]	_	_
15-4	2153-2154	,	_	_	_	_
15-5	2155-2171	hypermethylation	abstract	new	_	_
15-6	2172-2175	and	_	_	_	_
15-7	2176-2191	hypomethylation	abstract	new	coref	17-6
15-8	2192-2204	corresponded	_	_	_	_
15-9	2205-2207	to	_	_	_	_
15-10	2208-2209	a	event[125]	new[125]	_	_
15-11	2210-2218	decrease	event[125]	new[125]	_	_
15-12	2219-2222	and	_	_	_	_
15-13	2223-2231	increase	_	_	_	_
15-14	2232-2234	in	_	_	_	_
15-15	2235-2239	gene	abstract|abstract[127]	giv|giv[127]	coref|coref|coref|coref	18-31|18-81[0_127]|18-31|18-81[0_127]
15-16	2240-2250	expression	abstract[127]	giv[127]	_	_
15-17	2251-2252	,	_	_	_	_
15-18	2253-2265	respectively	_	_	_	_
15-19	2266-2267	.	_	_	_	_

#Text=These results are generally in line with the idea that in tumors , elevated methylation is associated with transcriptional silencing , providing a mechanism for inactivation of genes with tumor-suppressor function .
16-1	2268-2273	These	abstract[128]	giv[128]	coref	18-6[141_128]
16-2	2274-2281	results	abstract[128]	giv[128]	_	_
16-3	2282-2285	are	_	_	_	_
16-4	2286-2295	generally	_	_	_	_
16-5	2296-2298	in	_	_	_	_
16-6	2299-2303	line	_	_	_	_
16-7	2304-2308	with	_	_	_	_
16-8	2309-2312	the	abstract[129]	new[129]	_	_
16-9	2313-2317	idea	abstract[129]	new[129]	_	_
16-10	2318-2322	that	_	_	_	_
16-11	2323-2325	in	_	_	_	_
16-12	2326-2332	tumors	object	giv	coref	25-50
16-13	2333-2334	,	_	_	_	_
16-14	2335-2343	elevated	abstract[131]	giv[131]	coref	18-79[0_131]
16-15	2344-2355	methylation	abstract[131]	giv[131]	_	_
16-16	2356-2358	is	_	_	_	_
16-17	2359-2369	associated	_	_	_	_
16-18	2370-2374	with	_	_	_	_
16-19	2375-2390	transcriptional	abstract[132]	new[132]	_	_
16-20	2391-2400	silencing	abstract[132]	new[132]	_	_
16-21	2401-2402	,	_	_	_	_
16-22	2403-2412	providing	_	_	_	_
16-23	2413-2414	a	abstract[133]	new[133]	coref	28-19[253_133]
16-24	2415-2424	mechanism	abstract[133]	new[133]	_	_
16-25	2425-2428	for	abstract[133]	new[133]	_	_
16-26	2429-2441	inactivation	abstract[133]|event[134]	new[133]|new[134]	_	_
16-27	2442-2444	of	abstract[133]|event[134]	new[133]|new[134]	_	_
16-28	2445-2450	genes	abstract[133]|event[134]|abstract	new[133]|new[134]|giv	coref	22-8[183_0]
16-29	2451-2455	with	abstract[133]|event[134]	new[133]|new[134]	_	_
16-30	2456-2472	tumor-suppressor	abstract[133]|event[134]|abstract[136]	new[133]|new[134]|new[136]	_	_
16-31	2473-2481	function	abstract[133]|event[134]|abstract[136]	new[133]|new[134]|new[136]	_	_
16-32	2482-2483	.	_	_	_	_

#Text=On the other hand , hypomethylation may result in the activation of potential oncogenes .
17-1	2484-2486	On	_	_	_	_
17-2	2487-2490	the	_	_	_	_
17-3	2491-2496	other	_	_	_	_
17-4	2497-2501	hand	_	_	_	_
17-5	2502-2503	,	_	_	_	_
17-6	2504-2519	hypomethylation	abstract	giv	_	_
17-7	2520-2523	may	_	_	_	_
17-8	2524-2530	result	_	_	_	_
17-9	2531-2533	in	_	_	_	_
17-10	2534-2537	the	event[138]	new[138]	_	_
17-11	2538-2548	activation	event[138]	new[138]	_	_
17-12	2549-2551	of	event[138]	new[138]	_	_
17-13	2552-2561	potential	event[138]|substance[139]	new[138]|new[139]	_	_
17-14	2562-2571	oncogenes	event[138]|substance[139]	new[138]|new[139]	_	_
17-15	2572-2573	.	_	_	_	_

#Text=To simplify the interpretation of the results , we distinguished two classes of aberrantly methylated CpGs : Those in promoters , i. e. , located in the 5 ’ promoter gene region , which includes regions from 1500 bp upstream of the TSS up to the first exon of the gene , and those in gene bodies , including exons , introns , and 3’UTR sequences . For 81 % of the CpGs located in promoters for which methylation and expression were correlated , the correlation was negative , in concordance with the overall model .
18-1	2574-2576	To	_	_	_	_
18-2	2577-2585	simplify	_	_	_	_
18-3	2586-2589	the	abstract[140]	new[140]	_	_
18-4	2590-2604	interpretation	abstract[140]	new[140]	_	_
18-5	2605-2607	of	abstract[140]	new[140]	_	_
18-6	2608-2611	the	abstract[140]|abstract[141]	new[140]|giv[141]	_	_
18-7	2612-2619	results	abstract[140]|abstract[141]	new[140]|giv[141]	_	_
18-8	2620-2621	,	_	_	_	_
18-9	2622-2624	we	person	giv	ana	23-5
18-10	2625-2638	distinguished	_	_	_	_
18-11	2639-2642	two	person[143]	new[143]	_	_
18-12	2643-2650	classes	person[143]	new[143]	_	_
18-13	2651-2653	of	person[143]	new[143]	_	_
18-14	2654-2664	aberrantly	person[143]|abstract[144]	new[143]|giv[144]	coref	18-72[163_144]
18-15	2665-2675	methylated	person[143]|abstract[144]	new[143]|giv[144]	_	_
18-16	2676-2680	CpGs	person[143]|abstract[144]	new[143]|giv[144]	_	_
18-17	2681-2682	:	_	_	_	_
18-18	2683-2688	Those	_	_	_	_
18-19	2689-2691	in	_	_	_	_
18-20	2692-2701	promoters	person	new	coref	18-76
18-21	2702-2703	,	_	_	_	_
18-22	2704-2706	i.	_	_	_	_
18-23	2707-2709	e.	_	_	_	_
18-24	2710-2711	,	_	_	_	_
18-25	2712-2719	located	_	_	_	_
18-26	2720-2722	in	_	_	_	_
18-27	2723-2726	the	place[149]	new[149]	_	_
18-28	2727-2728	5	quantity[146]|place[149]	new[146]|new[149]	_	_
18-29	2729-2730	’	quantity[146]|place[149]	new[146]|new[149]	_	_
18-30	2731-2739	promoter	person|place[149]	new|new[149]	coref	22-23
18-31	2740-2744	gene	abstract|place[149]	giv|new[149]	coref	18-50[155_0]
18-32	2745-2751	region	place[149]	new[149]	_	_
18-33	2752-2753	,	_	_	_	_
18-34	2754-2759	which	_	_	_	_
18-35	2760-2768	includes	_	_	_	_
18-36	2769-2776	regions	place[150]	new[150]	_	_
18-37	2777-2781	from	place[150]	new[150]	_	_
18-38	2782-2786	1500	place[150]|place[152]	new[150]|new[152]	_	_
18-39	2787-2789	bp	place[150]|abstract|place[152]	new[150]|new|new[152]	_	_
18-40	2790-2798	upstream	place[150]|place[152]	new[150]|new[152]	_	_
18-41	2799-2801	of	place[150]|place[152]	new[150]|new[152]	_	_
18-42	2802-2805	the	place[150]|place[152]|abstract[153]	new[150]|new[152]|new[153]	_	_
18-43	2806-2809	TSS	place[150]|place[152]|abstract[153]	new[150]|new[152]|new[153]	_	_
18-44	2810-2812	up	place[150]|place[152]|abstract[153]	new[150]|new[152]|new[153]	_	_
18-45	2813-2815	to	place[150]|place[152]	new[150]|new[152]	_	_
18-46	2816-2819	the	place[150]|place[152]|abstract[154]	new[150]|new[152]|new[154]	_	_
18-47	2820-2825	first	place[150]|place[152]|abstract[154]	new[150]|new[152]|new[154]	_	_
18-48	2826-2830	exon	place[150]|place[152]|abstract[154]	new[150]|new[152]|new[154]	_	_
18-49	2831-2833	of	place[150]|place[152]|abstract[154]	new[150]|new[152]|new[154]	_	_
18-50	2834-2837	the	place[150]|place[152]|abstract[154]|abstract[155]	new[150]|new[152]|new[154]|giv[155]	coref	18-56[0_155]
18-51	2838-2842	gene	place[150]|place[152]|abstract[154]|abstract[155]	new[150]|new[152]|new[154]|giv[155]	_	_
18-52	2843-2844	,	place[150]|place[152]	new[150]|new[152]	_	_
18-53	2845-2848	and	place[150]|place[152]	new[150]|new[152]	_	_
18-54	2849-2854	those	place[150]|place[152]	new[150]|new[152]	_	_
18-55	2855-2857	in	place[150]|place[152]	new[150]|new[152]	_	_
18-56	2858-2862	gene	place[150]|place[152]|abstract|object[157]	new[150]|new[152]|giv|new[157]	coref|coref|coref|coref	21-9|21-9[177_157]|21-9|21-9[177_157]
18-57	2863-2869	bodies	place[150]|place[152]|object[157]	new[150]|new[152]|new[157]	_	_
18-58	2870-2871	,	place[150]|place[152]|object[157]	new[150]|new[152]|new[157]	_	_
18-59	2872-2881	including	place[150]|place[152]|object[157]	new[150]|new[152]|new[157]	_	_
18-60	2882-2887	exons	place[150]|place[152]|object[157]|abstract	new[150]|new[152]|new[157]|new	_	_
18-61	2888-2889	,	place[150]|place[152]|object[157]	new[150]|new[152]|new[157]	_	_
18-62	2890-2897	introns	place[150]|place[152]|object[157]|person	new[150]|new[152]|new[157]|new	_	_
18-63	2898-2899	,	place[150]|place[152]|object[157]	new[150]|new[152]|new[157]	_	_
18-64	2900-2903	and	place[150]|place[152]|object[157]	new[150]|new[152]|new[157]	_	_
18-65	2904-2909	3’UTR	place[150]|place[152]|object[157]|abstract|abstract[161]	new[150]|new[152]|new[157]|new|new[161]	_	_
18-66	2910-2919	sequences	place[150]|place[152]|object[157]|abstract[161]	new[150]|new[152]|new[157]|new[161]	_	_
18-67	2920-2921	.	place[150]|place[152]|object[157]|abstract[161]	new[150]|new[152]|new[157]|new[161]	_	_
18-68	2922-2925	For	place[150]|place[152]|object[157]|abstract[161]	new[150]|new[152]|new[157]|new[161]	_	_
18-69	2926-2928	81	place[150]|place[152]|object[157]|abstract[161]|quantity[162]	new[150]|new[152]|new[157]|new[161]|new[162]	_	_
18-70	2929-2930	%	place[150]|place[152]|object[157]|abstract[161]|quantity[162]	new[150]|new[152]|new[157]|new[161]|new[162]	_	_
18-71	2931-2933	of	place[150]|place[152]|object[157]|abstract[161]|quantity[162]	new[150]|new[152]|new[157]|new[161]|new[162]	_	_
18-72	2934-2937	the	place[150]|place[152]|object[157]|abstract[161]|quantity[162]|abstract[163]	new[150]|new[152]|new[157]|new[161]|new[162]|giv[163]	coref	20-1[0_163]
18-73	2938-2942	CpGs	place[150]|place[152]|object[157]|abstract[161]|quantity[162]|abstract[163]	new[150]|new[152]|new[157]|new[161]|new[162]|giv[163]	_	_
18-74	2943-2950	located	_	_	_	_
18-75	2951-2953	in	_	_	_	_
18-76	2954-2963	promoters	person	giv	coref	21-19
18-77	2964-2967	for	_	_	_	_
18-78	2968-2973	which	_	_	_	_
18-79	2974-2985	methylation	abstract|abstract[166]	giv|giv[166]	coref|coref|coref|coref	22-1[182_0]|26-20[236_166]|22-1[182_0]|26-20[236_166]
18-80	2986-2989	and	abstract[166]	giv[166]	_	_
18-81	2990-3000	expression	abstract[166]|abstract	giv[166]|giv	coref	20-15[174_0]
18-82	3001-3005	were	_	_	_	_
18-83	3006-3016	correlated	_	_	_	_
18-84	3017-3018	,	_	_	_	_
18-85	3019-3022	the	abstract[168]	giv[168]	coref	25-9[216_168]
18-86	3023-3034	correlation	abstract[168]	giv[168]	_	_
18-87	3035-3038	was	_	_	_	_
18-88	3039-3047	negative	_	_	_	_
18-89	3048-3049	,	_	_	_	_
18-90	3050-3052	in	_	_	_	_
18-91	3053-3064	concordance	abstract[169]	new[169]	_	_
18-92	3065-3069	with	abstract[169]	new[169]	_	_
18-93	3070-3073	the	abstract[169]|abstract[170]	new[169]|new[170]	_	_
18-94	3074-3081	overall	abstract[169]|abstract[170]	new[169]|new[170]	_	_
18-95	3082-3087	model	abstract[169]|abstract[170]	new[169]|new[170]	_	_
18-96	3088-3089	.	_	_	_	_

#Text=Approximately one-third of all methylation/expression-correlated
19-1	3090-3103	Approximately	quantity[171]	new[171]	_	_
19-2	3104-3113	one-third	quantity[171]	new[171]	_	_
19-3	3114-3116	of	quantity[171]	new[171]	_	_
19-4	3117-3120	all	quantity[171]|abstract[172]	new[171]|new[172]	_	_
19-5	3121-3154	methylation/expression-correlated	quantity[171]|abstract[172]	new[171]|new[172]	_	_

#Text=CpGs were positively correlated , i. e. , hypermethylation and hypomethylation were associated with increased and decreased expression , respectively .
20-1	3155-3159	CpGs	abstract	giv	coref	21-2[175_0]
20-2	3160-3164	were	_	_	_	_
20-3	3165-3175	positively	_	_	_	_
20-4	3176-3186	correlated	_	_	_	_
20-5	3187-3188	,	_	_	_	_
20-6	3189-3191	i.	_	_	_	_
20-7	3192-3194	e.	_	_	_	_
20-8	3195-3196	,	_	_	_	_
20-9	3197-3213	hypermethylation	_	_	_	_
20-10	3214-3217	and	_	_	_	_
20-11	3218-3233	hypomethylation	_	_	_	_
20-12	3234-3238	were	_	_	_	_
20-13	3239-3249	associated	_	_	_	_
20-14	3250-3254	with	_	_	_	_
20-15	3255-3264	increased	abstract[174]	giv[174]	coref	22-20[187_174]
20-16	3265-3268	and	abstract[174]	giv[174]	_	_
20-17	3269-3278	decreased	abstract[174]	giv[174]	_	_
20-18	3279-3289	expression	abstract[174]	giv[174]	_	_
20-19	3290-3291	,	_	_	_	_
20-20	3292-3304	respectively	_	_	_	_
20-21	3305-3306	.	_	_	_	_

#Text=Among these CpGs , most are located in gene bodies , whereas only 22 % are located in promoters , consistent with previously published reports .
21-1	3307-3312	Among	_	_	_	_
21-2	3313-3318	these	abstract[175]	giv[175]	_	_
21-3	3319-3323	CpGs	abstract[175]	giv[175]	_	_
21-4	3324-3325	,	_	_	_	_
21-5	3326-3330	most	_	_	_	_
21-6	3331-3334	are	_	_	_	_
21-7	3335-3342	located	_	_	_	_
21-8	3343-3345	in	_	_	_	_
21-9	3346-3350	gene	abstract|object[177]	giv|giv[177]	coref|coref|coref|coref	22-20|22-33[192_177]|22-20|22-33[192_177]
21-10	3351-3357	bodies	object[177]	giv[177]	_	_
21-11	3358-3359	,	_	_	_	_
21-12	3360-3367	whereas	_	_	_	_
21-13	3368-3372	only	quantity[178]	new[178]	_	_
21-14	3373-3375	22	quantity[178]	new[178]	_	_
21-15	3376-3377	%	quantity[178]	new[178]	_	_
21-16	3378-3381	are	_	_	_	_
21-17	3382-3389	located	_	_	_	_
21-18	3390-3392	in	_	_	_	_
21-19	3393-3402	promoters	place	giv	_	_
21-20	3403-3404	,	_	_	_	_
21-21	3405-3415	consistent	_	_	_	_
21-22	3416-3420	with	_	_	_	_
21-23	3421-3431	previously	abstract[180]	new[180]	_	_
21-24	3432-3441	published	abstract[180]	new[180]	_	_
21-25	3442-3449	reports	abstract[180]	new[180]	_	_
21-26	3450-3451	.	_	_	_	_

#Text=Gene body methylation has been observed in active genes , implying that it may have the opposite effect on gene expression to promoter methylation , i. e. , increased DNA methylation in gene bodies may promote transcription .
22-1	3452-3456	Gene	abstract[182]	giv[182]	ana	22-13[0_182]
22-2	3457-3461	body	object|abstract[182]	new|giv[182]	_	_
22-3	3462-3473	methylation	abstract[182]	giv[182]	_	_
22-4	3474-3477	has	_	_	_	_
22-5	3478-3482	been	_	_	_	_
22-6	3483-3491	observed	_	_	_	_
22-7	3492-3494	in	_	_	_	_
22-8	3495-3501	active	abstract[183]	giv[183]	coref	24-11[210_183]
22-9	3502-3507	genes	abstract[183]	giv[183]	_	_
22-10	3508-3509	,	_	_	_	_
22-11	3510-3518	implying	_	_	_	_
22-12	3519-3523	that	_	_	_	_
22-13	3524-3526	it	abstract	giv	coref	22-23[189_0]
22-14	3527-3530	may	_	_	_	_
22-15	3531-3535	have	_	_	_	_
22-16	3536-3539	the	abstract[185]	new[185]	_	_
22-17	3540-3548	opposite	abstract[185]	new[185]	_	_
22-18	3549-3555	effect	abstract[185]	new[185]	_	_
22-19	3556-3558	on	abstract[185]	new[185]	_	_
22-20	3559-3563	gene	abstract[185]|abstract|abstract[187]	new[185]|giv|giv[187]	coref|coref|coref|coref	23-8[0_187]|25-38[225_0]|23-8[0_187]|25-38[225_0]
22-21	3564-3574	expression	abstract[185]|abstract[187]	new[185]|giv[187]	_	_
22-22	3575-3577	to	abstract[185]|abstract[187]	new[185]|giv[187]	_	_
22-23	3578-3586	promoter	abstract[185]|abstract[187]|person|abstract[189]	new[185]|giv[187]|giv|giv[189]	coref|coref	22-29[191_189]|22-29[191_189]
22-24	3587-3598	methylation	abstract[185]|abstract[187]|abstract[189]	new[185]|giv[187]|giv[189]	_	_
22-25	3599-3600	,	abstract[185]|abstract[187]	new[185]|giv[187]	_	_
22-26	3601-3603	i.	abstract[185]|abstract[187]	new[185]|giv[187]	_	_
22-27	3604-3606	e.	abstract[185]|abstract[187]	new[185]|giv[187]	_	_
22-28	3607-3608	,	_	_	_	_
22-29	3609-3618	increased	abstract[191]	giv[191]	coref	26-20[235_191]
22-30	3619-3622	DNA	substance|abstract[191]	giv|giv[191]	coref	26-20
22-31	3623-3634	methylation	abstract[191]	giv[191]	_	_
22-32	3635-3637	in	abstract[191]	giv[191]	_	_
22-33	3638-3642	gene	abstract[191]|object[192]	giv[191]|giv[192]	_	_
22-34	3643-3649	bodies	abstract[191]|object[192]	giv[191]|giv[192]	_	_
22-35	3650-3653	may	_	_	_	_
22-36	3654-3661	promote	_	_	_	_
22-37	3662-3675	transcription	abstract	new	_	_
22-38	3676-3677	.	_	_	_	_

#Text=In this study , we compared the expression profiles of NFPAs and normal pituitary sections without evidence of neoplastic features , obtained by Rathke ’s cleft cyst surgery .
23-1	3678-3680	In	_	_	_	_
23-2	3681-3685	this	abstract[194]	giv[194]	_	_
23-3	3686-3691	study	abstract[194]	giv[194]	_	_
23-4	3692-3693	,	_	_	_	_
23-5	3694-3696	we	person	giv	ana	24-3
23-6	3697-3705	compared	_	_	_	_
23-7	3706-3709	the	object[197]	new[197]	_	_
23-8	3710-3720	expression	abstract|object[197]	giv|new[197]	coref	24-14[211_0]
23-9	3721-3729	profiles	object[197]	new[197]	_	_
23-10	3730-3732	of	object[197]	new[197]	_	_
23-11	3733-3738	NFPAs	object[197]|object|abstract[199]	new[197]|giv|new[199]	coref|coref|coref|coref	28-12|28-12[250_199]|28-12|28-12[250_199]
23-12	3739-3742	and	object[197]|abstract[199]	new[197]|new[199]	_	_
23-13	3743-3749	normal	object[197]|abstract[199]|plant[201]	new[197]|new[199]|giv[201]	_	_
23-14	3750-3759	pituitary	object[197]|abstract[199]|person|plant[201]	new[197]|new[199]|giv|giv[201]	coref	28-14
23-15	3760-3768	sections	object[197]|abstract[199]|plant[201]	new[197]|new[199]|giv[201]	_	_
23-16	3769-3776	without	_	_	_	_
23-17	3777-3785	evidence	abstract[202]	new[202]	_	_
23-18	3786-3788	of	abstract[202]	new[202]	_	_
23-19	3789-3799	neoplastic	abstract[202]|abstract[203]	new[202]|new[203]	_	_
23-20	3800-3808	features	abstract[202]|abstract[203]	new[202]|new[203]	_	_
23-21	3809-3810	,	_	_	_	_
23-22	3811-3819	obtained	_	_	_	_
23-23	3820-3822	by	_	_	_	_
23-24	3823-3829	Rathke	person[204]|event[206]	new[204]|new[206]	ana|ana	24-1[0_206]|24-1[0_206]
23-25	3830-3832	’s	person[204]|event[206]	new[204]|new[206]	_	_
23-26	3833-3838	cleft	event[206]	new[206]	_	_
23-27	3839-3843	cyst	object|event[206]	new|new[206]	_	_
23-28	3844-3851	surgery	event[206]	new[206]	_	_
23-29	3852-3853	.	_	_	_	_

#Text=This allowed us to identify DEGs and investigate which of these genes exhibits methylation-dependent expression .
24-1	3854-3858	This	event	giv	_	_
24-2	3859-3866	allowed	_	_	_	_
24-3	3867-3869	us	person	giv	ana	25-2
24-4	3870-3872	to	_	_	_	_
24-5	3873-3881	identify	_	_	_	_
24-6	3882-3886	DEGs	abstract	new	coref	25-15
24-7	3887-3890	and	_	_	_	_
24-8	3891-3902	investigate	_	_	_	_
24-9	3903-3908	which	_	_	_	_
24-10	3909-3911	of	_	_	_	_
24-11	3912-3917	these	abstract[210]	giv[210]	coref	25-7[214_210]
24-12	3918-3923	genes	abstract[210]	giv[210]	_	_
24-13	3924-3932	exhibits	_	_	_	_
24-14	3933-3954	methylation-dependent	abstract[211]	giv[211]	coref	25-26[0_211]
24-15	3955-3965	expression	abstract[211]	giv[211]	_	_
24-16	3966-3967	.	_	_	_	_

#Text=When we compared the list of genes with methylation/expression correlation and the list of DEGs , most genes were hypermethylated with a fold change in expression corresponding to the sign of the correlation , e. g. , a gene with negative methylation/expression correlation that was hypermethylated and downregulated in tumors .
25-1	3968-3972	When	_	_	_	_
25-2	3973-3975	we	person	giv	ana	28-1
25-3	3976-3984	compared	_	_	_	_
25-4	3985-3988	the	abstract[213]	new[213]	_	_
25-5	3989-3993	list	abstract[213]	new[213]	_	_
25-6	3994-3996	of	abstract[213]	new[213]	_	_
25-7	3997-4002	genes	abstract[213]|abstract[214]	new[213]|giv[214]	coref	25-17[219_214]
25-8	4003-4007	with	abstract[213]|abstract[214]	new[213]|giv[214]	_	_
25-9	4008-4030	methylation/expression	abstract[213]|abstract[214]|quantity|abstract[216]	new[213]|giv[214]|new|giv[216]	coref|coref|coref|coref	25-32[224_216]|25-42|25-32[224_216]|25-42
25-10	4031-4042	correlation	abstract[213]|abstract[214]|abstract[216]	new[213]|giv[214]|giv[216]	_	_
25-11	4043-4046	and	abstract[213]|abstract[214]	new[213]|giv[214]	_	_
25-12	4047-4050	the	abstract[213]|abstract[214]|object[217]	new[213]|giv[214]|new[217]	_	_
25-13	4051-4055	list	abstract[213]|abstract[214]|object[217]	new[213]|giv[214]|new[217]	_	_
25-14	4056-4058	of	abstract[213]|abstract[214]|object[217]	new[213]|giv[214]|new[217]	_	_
25-15	4059-4063	DEGs	abstract[213]|abstract[214]|object[217]|abstract	new[213]|giv[214]|new[217]|giv	coref	29-18
25-16	4064-4065	,	_	_	_	_
25-17	4066-4070	most	abstract[219]	giv[219]	coref	26-5[0_219]
25-18	4071-4076	genes	abstract[219]	giv[219]	_	_
25-19	4077-4081	were	_	_	_	_
25-20	4082-4097	hypermethylated	_	_	_	_
25-21	4098-4102	with	_	_	_	_
25-22	4103-4104	a	abstract[221]	new[221]	coref	26-9[231_221]
25-23	4105-4109	fold	place|abstract[221]	new|new[221]	_	_
25-24	4110-4116	change	abstract[221]	new[221]	_	_
25-25	4117-4119	in	_	_	_	_
25-26	4120-4130	expression	abstract	giv	coref	26-13
25-27	4131-4144	corresponding	_	_	_	_
25-28	4145-4147	to	_	_	_	_
25-29	4148-4151	the	abstract[223]	new[223]	coref	26-23[237_223]
25-30	4152-4156	sign	abstract[223]	new[223]	_	_
25-31	4157-4159	of	abstract[223]	new[223]	_	_
25-32	4160-4163	the	abstract[223]|abstract[224]	new[223]|giv[224]	coref	25-41[227_224]
25-33	4164-4175	correlation	abstract[223]|abstract[224]	new[223]|giv[224]	_	_
25-34	4176-4177	,	_	_	_	_
25-35	4178-4180	e.	_	_	_	_
25-36	4181-4183	g.	_	_	_	_
25-37	4184-4185	,	_	_	_	_
25-38	4186-4187	a	abstract[225]	giv[225]	_	_
25-39	4188-4192	gene	abstract[225]	giv[225]	_	_
25-40	4193-4197	with	abstract[225]	giv[225]	_	_
25-41	4198-4206	negative	abstract[225]|abstract[227]	giv[225]|giv[227]	coref	26-26[238_227]
25-42	4207-4229	methylation/expression	abstract[225]|quantity|abstract[227]	giv[225]|giv|giv[227]	coref	26-37
25-43	4230-4241	correlation	abstract[225]|abstract[227]	giv[225]|giv[227]	_	_
25-44	4242-4246	that	_	_	_	_
25-45	4247-4250	was	_	_	_	_
25-46	4251-4266	hypermethylated	_	_	_	_
25-47	4267-4270	and	_	_	_	_
25-48	4271-4284	downregulated	_	_	_	_
25-49	4285-4287	in	_	_	_	_
25-50	4288-4294	tumors	object	giv	coref	26-43
25-51	4295-4296	.	_	_	_	_

#Text=In a subset of genes , however , the fold change in expression was inconsistent with the difference in DNA methylation and the sign of the correlation , e. g. , a hypermethylated gene with negative methylation/expression correlation that was upregulated in tumors .
26-1	4297-4299	In	_	_	_	_
26-2	4300-4301	a	quantity[229]	new[229]	_	_
26-3	4302-4308	subset	quantity[229]	new[229]	_	_
26-4	4309-4311	of	quantity[229]	new[229]	_	_
26-5	4312-4317	genes	quantity[229]|abstract	new[229]|giv	coref	27-1[243_0]
26-6	4318-4319	,	_	_	_	_
26-7	4320-4327	however	_	_	_	_
26-8	4328-4329	,	_	_	_	_
26-9	4330-4333	the	abstract[231]	giv[231]	_	_
26-10	4334-4338	fold	abstract[231]	giv[231]	_	_
26-11	4339-4345	change	abstract[231]	giv[231]	_	_
26-12	4346-4348	in	abstract[231]	giv[231]	_	_
26-13	4349-4359	expression	abstract[231]|abstract	giv[231]|giv	_	_
26-14	4360-4363	was	_	_	_	_
26-15	4364-4376	inconsistent	_	_	_	_
26-16	4377-4381	with	_	_	_	_
26-17	4382-4385	the	abstract[233]	new[233]	_	_
26-18	4386-4396	difference	abstract[233]	new[233]	_	_
26-19	4397-4399	in	abstract[233]	new[233]	_	_
26-20	4400-4403	DNA	abstract[233]|abstract|abstract[235]|abstract[236]	new[233]|giv|giv[235]|giv[236]	coref|coref|coref|coref|coref|coref	28-24|28-23[255_235]|28-24|28-23[255_235]|28-24|28-23[255_235]
26-21	4404-4415	methylation	abstract[233]|abstract[235]|abstract[236]	new[233]|giv[235]|giv[236]	_	_
26-22	4416-4419	and	abstract[233]|abstract[236]	new[233]|giv[236]	_	_
26-23	4420-4423	the	abstract[233]|abstract[236]|abstract[237]	new[233]|giv[236]|giv[237]	_	_
26-24	4424-4428	sign	abstract[233]|abstract[236]|abstract[237]	new[233]|giv[236]|giv[237]	_	_
26-25	4429-4431	of	abstract[233]|abstract[236]|abstract[237]	new[233]|giv[236]|giv[237]	_	_
26-26	4432-4435	the	abstract[233]|abstract[236]|abstract[237]|abstract[238]	new[233]|giv[236]|giv[237]|giv[238]	appos	26-29[239_238]
26-27	4436-4447	correlation	abstract[233]|abstract[236]|abstract[237]|abstract[238]	new[233]|giv[236]|giv[237]|giv[238]	_	_
26-28	4448-4449	,	_	_	_	_
26-29	4450-4452	e.	abstract[239]	giv[239]	appos	26-32[240_239]
26-30	4453-4455	g.	abstract[239]	giv[239]	_	_
26-31	4456-4457	,	_	_	_	_
26-32	4458-4459	a	abstract[240]	giv[240]	_	_
26-33	4460-4475	hypermethylated	abstract[240]	giv[240]	_	_
26-34	4476-4480	gene	abstract[240]	giv[240]	_	_
26-35	4481-4485	with	abstract[240]	giv[240]	_	_
26-36	4486-4494	negative	abstract[240]	giv[240]	_	_
26-37	4495-4517	methylation/expression	abstract[240]|quantity	giv[240]|giv	_	_
26-38	4518-4529	correlation	abstract[240]	giv[240]	_	_
26-39	4530-4534	that	_	_	_	_
26-40	4535-4538	was	_	_	_	_
26-41	4539-4550	upregulated	_	_	_	_
26-42	4551-4553	in	_	_	_	_
26-43	4554-4560	tumors	object	giv	_	_
26-44	4561-4562	.	_	_	_	_

#Text=These genes were excluded from the functional GSEA .
27-1	4563-4568	These	abstract[243]	giv[243]	coref	28-9[248_243]
27-2	4569-4574	genes	abstract[243]	giv[243]	_	_
27-3	4575-4579	were	_	_	_	_
27-4	4580-4588	excluded	_	_	_	_
27-5	4589-4593	from	_	_	_	_
27-6	4594-4597	the	event[244]	giv[244]	_	_
27-7	4598-4608	functional	event[244]	giv[244]	_	_
27-8	4609-4613	GSEA	event[244]	giv[244]	_	_
27-9	4614-4615	.	_	_	_	_

#Text=We believe that the differential the expression of these genes in NFPAs and pituitary tissue was due to a mechanism distinct from aberrant DNA methylation , despite the fact that the expression levels of these genes were methylation-related .
28-1	4616-4618	We	person	giv	ana	29-4
28-2	4619-4626	believe	_	_	_	_
28-3	4627-4631	that	_	_	_	_
28-4	4632-4635	the	abstract[246]	new[246]	_	_
28-5	4636-4648	differential	abstract[246]	new[246]	_	_
28-6	4649-4652	the	abstract[247]	new[247]	coref	28-32[0_247]
28-7	4653-4663	expression	abstract[247]	new[247]	_	_
28-8	4664-4666	of	abstract[247]	new[247]	_	_
28-9	4667-4672	these	abstract[247]|abstract[248]	new[247]|giv[248]	coref	28-35[259_248]
28-10	4673-4678	genes	abstract[247]|abstract[248]	new[247]|giv[248]	_	_
28-11	4679-4681	in	abstract[247]|abstract[248]	new[247]|giv[248]	_	_
28-12	4682-4687	NFPAs	abstract[247]|abstract[248]|object|abstract[250]	new[247]|giv[248]|giv|giv[250]	coref|coref	29-9[263_0]|29-9[263_0]
28-13	4688-4691	and	abstract[247]|abstract[248]|abstract[250]	new[247]|giv[248]|giv[250]	_	_
28-14	4692-4701	pituitary	abstract[247]|abstract[248]|abstract[250]|abstract|object[252]	new[247]|giv[248]|giv[250]|giv|new[252]	_	_
28-15	4702-4708	tissue	abstract[247]|abstract[248]|abstract[250]|object[252]	new[247]|giv[248]|giv[250]|new[252]	_	_
28-16	4709-4712	was	_	_	_	_
28-17	4713-4716	due	_	_	_	_
28-18	4717-4719	to	_	_	_	_
28-19	4720-4721	a	abstract[253]	giv[253]	_	_
28-20	4722-4731	mechanism	abstract[253]	giv[253]	_	_
28-21	4732-4740	distinct	abstract[253]	giv[253]	_	_
28-22	4741-4745	from	_	_	_	_
28-23	4746-4754	aberrant	abstract[255]	giv[255]	coref	29-22[267_255]
28-24	4755-4758	DNA	abstract|abstract[255]	giv|giv[255]	_	_
28-25	4759-4770	methylation	abstract[255]	giv[255]	_	_
28-26	4771-4772	,	_	_	_	_
28-27	4773-4780	despite	_	_	_	_
28-28	4781-4784	the	abstract[256]	new[256]	_	_
28-29	4785-4789	fact	abstract[256]	new[256]	_	_
28-30	4790-4794	that	abstract[256]	new[256]	_	_
28-31	4795-4798	the	abstract[256]|abstract[258]	new[256]|new[258]	_	_
28-32	4799-4809	expression	abstract[256]|abstract|abstract[258]	new[256]|giv|new[258]	_	_
28-33	4810-4816	levels	abstract[256]|abstract[258]	new[256]|new[258]	_	_
28-34	4817-4819	of	abstract[256]|abstract[258]	new[256]|new[258]	_	_
28-35	4820-4825	these	abstract[256]|abstract[258]|abstract[259]	new[256]|new[258]|giv[259]	_	_
28-36	4826-4831	genes	abstract[256]|abstract[258]|abstract[259]	new[256]|new[258]|giv[259]	_	_
28-37	4832-4836	were	abstract[256]	new[256]	_	_
28-38	4837-4856	methylation-related	abstract[256]	new[256]	_	_
28-39	4857-4858	.	_	_	_	_

#Text=In general , our analysis showed that in gonadotroph NFPAs , the expression of 9 % of DEGs is correlated with aberrant methylation .
29-1	4859-4861	In	_	_	_	_
29-2	4862-4869	general	abstract	new	_	_
29-3	4870-4871	,	_	_	_	_
29-4	4872-4875	our	person|abstract[262]	giv|giv[262]	_	_
29-5	4876-4884	analysis	abstract[262]	giv[262]	_	_
29-6	4885-4891	showed	_	_	_	_
29-7	4892-4896	that	_	_	_	_
29-8	4897-4899	in	_	_	_	_
29-9	4900-4911	gonadotroph	object[263]	giv[263]	_	_
29-10	4912-4917	NFPAs	object[263]	giv[263]	_	_
29-11	4918-4919	,	_	_	_	_
29-12	4920-4923	the	abstract[264]	new[264]	_	_
29-13	4924-4934	expression	abstract[264]	new[264]	_	_
29-14	4935-4937	of	abstract[264]	new[264]	_	_
29-15	4938-4939	9	abstract[264]|quantity[265]	new[264]|new[265]	_	_
29-16	4940-4941	%	abstract[264]|quantity[265]	new[264]|new[265]	_	_
29-17	4942-4944	of	abstract[264]|quantity[265]	new[264]|new[265]	_	_
29-18	4945-4949	DEGs	abstract[264]|quantity[265]|abstract	new[264]|new[265]|giv	_	_
29-19	4950-4952	is	_	_	_	_
29-20	4953-4963	correlated	_	_	_	_
29-21	4964-4968	with	_	_	_	_
29-22	4969-4977	aberrant	abstract[267]	giv[267]	_	_
29-23	4978-4989	methylation	abstract[267]	giv[267]	_	_
29-24	4990-4991	.	_	_	_	_
